Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

14 Nov 2017

Abstract excerpt

Abstract Purpose: We investigated MYCN-regulated molecular pathways in castration-resistant prostate cancer (CRPC) classified by morphologic criteria as adenocarcinoma or neuroendocrine to extend the molecular phenotype, establish driver pathways, and identify novel approaches to combination therapy for neuroendocrine prostate cancer (NEPC). Experimental Design and Results: Using comparative bioinformatics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29138344
DOI: 10.1158/1078-0432.ccr-17-1872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate CancerPMID 29138344Read ↗

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsSemantic proximity Read ↗

KDM4A promotes the progression of neuroendocrine prostate cancerSemantic proximity Read ↗

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathwaySemantic proximity Read ↗

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.Semantic proximity Read ↗

Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate CancerSemantic proximity Read ↗

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.Semantic proximity Read ↗

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read ↗

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13Semantic proximity Read ↗

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerSemantic proximity Read ↗

Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 ExpressionSemantic proximity Read ↗

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerSemantic proximity Read ↗

An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and ProspectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.